Last reviewed · How we verify
Familial x-linked hypophosphatemic vitamin D refractory rickets
Approved treatments
- Drisdol · Esjay Pharma
- Crysvita · Ultragenyx Pharm Inc
Burosumab-twza binds to and inhibits FGF23, restoring renal phosphate reabsorption and increasing 1,25 dihydroxy vitamin D levels. - Calciferol · Department of Medical Services Ministry of Public Health of Thailand
- CRYSVITA · KYOWA KIRIN
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Familial x-linked hypophosphatemic vitamin D refractory rickets patent landscape — cliff calendar, originator estates, attackable patents
- Familial x-linked hypophosphatemic vitamin D refractory rickets treatment landscape brief
- Familial x-linked hypophosphatemic vitamin D refractory rickets treatment updates RSS
Frequently asked questions about Familial x-linked hypophosphatemic vitamin D refractory rickets
What drugs treat Familial x-linked hypophosphatemic vitamin D refractory rickets?
Tracked treatments include Drisdol, Crysvita, Calciferol, CRYSVITA.
What is the treatment for Familial x-linked hypophosphatemic vitamin D refractory rickets?
Standard treatment for Familial x-linked hypophosphatemic vitamin D refractory rickets includes Drisdol, Crysvita, Calciferol, CRYSVITA. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Familial x-linked hypophosphatemic vitamin D refractory rickets patent cliff · Familial x-linked hypophosphatemic vitamin D refractory rickets CI report
- Treatment: Drisdol · Esjay Pharma
- Treatment: Crysvita · Ultragenyx Pharm Inc
- Treatment: Calciferol · Department of Medical Services Ministry of Public Health of Thailand
- Treatment: CRYSVITA · KYOWA KIRIN
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing